Display options
Cite
Ferrari B, Roda E, Priori EC, et al. A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma. Front Neurosci. 2021;15:589906doi: 10.3389/fnins.2021.589906.
Ferrari, B., Roda, E., Priori, E. C., De Luca, F., Facoetti, A., Ravera, M., Brandalise, F., Locatelli, C. A., Rossi, P., & Bottone, M. G. (2021). A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma. Frontiers in neuroscience, 15589906. https://doi.org/10.3389/fnins.2021.589906
Ferrari, Beatrice, et al. "A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma." Frontiers in neuroscience vol. 15 (2021): 589906. doi: https://doi.org/10.3389/fnins.2021.589906
Ferrari B, Roda E, Priori EC, De Luca F, Facoetti A, Ravera M, Brandalise F, Locatelli CA, Rossi P, Bottone MG. A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma. Front Neurosci. 2021 Mar 22;15:589906. doi: 10.3389/fnins.2021.589906. eCollection 2021. PMID: 33828444; PMCID: PMC8019820.
Copy Download .nbib Format: NLM
Share it on

Front Neurosci. 2021 Mar 22;15:589906. doi: 10.3389/fnins.2021.589906. eCollection 2021.

A New Platinum-Based Prodrug Candidate for Chemotherapy and Its Synergistic Effect With Hadrontherapy: Novel Strategy to Treat Glioblastoma.

Frontiers in neuroscience

Beatrice Ferrari, Elisa Roda, Erica Cecilia Priori, Fabrizio De Luca, Angelica Facoetti, Mauro Ravera, Federico Brandalise, Carlo Alessandro Locatelli, Paola Rossi, Maria Grazia Bottone

Affiliations

  1. Department of Biology and Biotechnology "L. Spallanzani", University of Pavia, Pavia, Italy.
  2. Laboratory of Clinical & Experimental Toxicology, Pavia Poison Centre, National Toxicology Information Centre, Toxicology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
  3. National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy.
  4. Department of Sciences and Technological Innovation (DiSIT), University of Piemonte Orientale "A. Avogadro", Alessandria, Italy.
  5. Department of Fundamental Neurosciences (NEUFO), University of Geneva, Geneva, Switzerland.

PMID: 33828444 PMCID: PMC8019820 DOI: 10.3389/fnins.2021.589906

Abstract

Glioblastoma (GBM) is the most common tumor of the central nervous system. Current therapies, often associated with severe side effects, are inefficacious to contrast the GBM relapsing forms. In trying to overcome these drawbacks, (

Copyright © 2021 Ferrari, Roda, Priori, De Luca, Facoetti, Ravera, Brandalise, Locatelli, Rossi and Bottone.

Keywords: carbon ions irradiation effects; glioblastoma; glioblastoma (GBM); hadrontherapy; in vitro; platinum(IV) chemotherapeutics; tumor resistance

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Cell Mol Neurobiol. 2021 Apr;41(3):563-587 - PubMed
  2. Toxicol Appl Pharmacol. 2019 Feb 1;364:1-11 - PubMed
  3. Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):229-41 - PubMed
  4. J Exp Clin Cancer Res. 2019 Aug 30;38(1):382 - PubMed
  5. Neurotoxicol Teratol. 2011 Mar-Apr;33(2):273-81 - PubMed
  6. Med Phys. 2015 Sep;42(9):5287-300 - PubMed
  7. Radiother Oncol. 2019 Apr;133:77-86 - PubMed
  8. Sci Rep. 2014 Jul 01;4:5511 - PubMed
  9. Cell Death Dis. 2014 Nov 27;5:e1543 - PubMed
  10. Cancers (Basel). 2020 Oct 17;12(10): - PubMed
  11. Int J Oncol. 2007 Jul;31(1):161-8 - PubMed
  12. J Inorg Biochem. 2015 Sep;150:1-8 - PubMed
  13. Gene. 2013 Feb 15;515(1):208-13 - PubMed
  14. Exp Ther Med. 2015 Oct;10(4):1317-1323 - PubMed
  15. Int J Mol Sci. 2018 May 08;19(5): - PubMed
  16. Radiat Oncol. 2016 Sep 22;11(1):126 - PubMed
  17. Sci Rep. 2019 Apr 4;9(1):5632 - PubMed
  18. Toxicol Lett. 2015 Sep 17;237(3):219-27 - PubMed
  19. Histochem Cell Biol. 2016 May;145(5):587-601 - PubMed
  20. BMC Cancer. 2016 Nov 15;16(1):891 - PubMed
  21. Mol Cancer Ther. 2015 Aug;14(8):1794-804 - PubMed
  22. Cancer Radiother. 2015 Dec;19(8):775-89 - PubMed
  23. Chem Sci. 2016 Mar 1;7(3):2381-2391 - PubMed
  24. Radiat Prot Dosimetry. 2015 Sep;166(1-4):379-82 - PubMed
  25. Int J Mol Sci. 2019 Jun 30;20(13): - PubMed
  26. Cancer Res. 1986 Jun;46(6):2745-50 - PubMed
  27. Contemp Oncol (Pozn). 2014;18(5):307-12 - PubMed
  28. Cell Prolif. 2008 Jun;41(3):506-20 - PubMed
  29. Nat Commun. 2018 Jul 27;9(1):2949 - PubMed
  30. Cell. 2016 Oct 20;167(3):606-609 - PubMed
  31. Prog Neurol Surg. 2018;32:57-65 - PubMed
  32. Mutat Res Rev Mutat Res. 2016 Jul-Sep;769:19-35 - PubMed
  33. Chem Rev. 2016 Mar 9;116(5):3436-86 - PubMed
  34. Trends Cancer. 2015 Dec;1(4):252-265 - PubMed
  35. Mol Med Rep. 2018 Mar;17(3):4767-4776 - PubMed
  36. Sci Rep. 2017 Jun 16;7(1):3751 - PubMed
  37. Radiat Oncol. 2011 Sep 20;6:119 - PubMed
  38. Cell Mol Biol Lett. 2016 Dec 13;21:29 - PubMed
  39. Phys Med. 2015 Jun;31(4):333-51 - PubMed
  40. Neurotoxicology. 2013 Jan;34:51-60 - PubMed
  41. Front Oncol. 2020 May 05;10:535 - PubMed
  42. J Med Chem. 2019 Apr 11;62(7):3395-3406 - PubMed
  43. Expert Opin Investig Drugs. 2009 Nov;18(11):1605-17 - PubMed
  44. Ann Oncol. 2017 Nov 1;28(11):2670-2679 - PubMed
  45. Lancet Oncol. 2015 Feb;16(2):e93-e100 - PubMed
  46. Asian Pac J Cancer Prev. ;18(1):3-9 - PubMed
  47. Neurotox Res. 2020 Jan;37(1):183-197 - PubMed
  48. Histol Histopathol. 2011 Jul;26(7):831-42 - PubMed
  49. Radiother Oncol. 2013 Jul;108(1):132-5 - PubMed
  50. Oncol Rep. 2018 May;39(5):2333-2341 - PubMed
  51. Radiol Oncol. 2019 Mar 3;53(1):6-14 - PubMed
  52. Lancet Oncol. 2012 May;13(5):e187-8 - PubMed
  53. J Thorac Dis. 2018 Aug;10(Suppl 21):S2465-S2473 - PubMed
  54. JAMA Oncol. 2018 Sep 1;4(9):1254-1262 - PubMed
  55. Front Oncol. 2016 Jun 07;6:140 - PubMed
  56. J Biol. 2006;5(7):22 - PubMed
  57. Biomedicines. 2019 Sep 09;7(3): - PubMed
  58. Radiol Med. 2017 Feb;122(2):140-145 - PubMed
  59. Pharmacol Rev. 2002 Sep;54(3):375-429 - PubMed
  60. Dtsch Arztebl Int. 2018 May 21;115(20-21):356-364 - PubMed
  61. Commun Biol. 2018 Jan 22;1:6 - PubMed
  62. Life Sci. 2018 Oct 1;210:166-176 - PubMed
  63. Exp Ther Med. 2018 Feb;15(2):1959-1965 - PubMed
  64. Br J Radiol. 2015 Sep;88(1053):20150354 - PubMed
  65. J Peripher Nerv Syst. 2019 Oct;24 Suppl 2:S26-S39 - PubMed
  66. Int J Radiat Biol. 2015 Jan;91(1):90-8 - PubMed
  67. J Radiat Res. 2010;51(4):393-404 - PubMed
  68. Dalton Trans. 2017 Oct 24;46(41):14174-14185 - PubMed
  69. Future Oncol. 2011 Nov;7(11):1335-46 - PubMed
  70. Sci Rep. 2019 Feb 4;9(1):1282 - PubMed
  71. Int J Cell Biol. 2012;2012:424072 - PubMed
  72. Chin J Cancer. 2014 Jan;33(1):16-24 - PubMed
  73. Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S2-8 - PubMed
  74. Sci Transl Med. 2013 Feb 20;5(173):173sr2 - PubMed
  75. Dalton Trans. 2014 Jul 14;43(26):9813-20 - PubMed
  76. Front Immunol. 2020 Jan 21;10:3137 - PubMed
  77. Cell Death Dis. 2010 Jul 29;1:e60 - PubMed
  78. J Recept Signal Transduct Res. 2017 Feb;37(1):84-93 - PubMed
  79. Int J Dev Neurosci. 2015 Feb;40:24-34 - PubMed
  80. Cell Death Differ. 2018 Mar;25(3):486-541 - PubMed
  81. Curr Pharm Des. 2017;23(16):2366-2376 - PubMed
  82. Genes Dev. 2017 Jan 15;31(2):101-126 - PubMed
  83. Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):394-9 - PubMed
  84. N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed
  85. Eur J Pharmacol. 2014 Oct 5;740:364-78 - PubMed
  86. Biochem Pharmacol. 2011 Jan 1;81(1):91-103 - PubMed

Publication Types